Warning Letter — Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Pure Arylcyclohexylamine Store (www.arylcyclohexylamine.com) regarding the sale and distribution of products via their website. The agency's action targets the marketing and sale of arylcyclohexylamine derivatives, which the source identifies as a regulatory violation.
This affects online chemical and specialty pharmaceutical retailers, as well as regulatory and legal departments responsible for monitoring digital sales channels and product classification.
The source indicates that CDER is actively monitoring and taking enforcement action against online entities selling arylcyclohexylamine compounds. This suggests a continued prioritization of controlling the distribution of chemically specific research chemicals or analogs that may be marketed for unapproved drug uses. Entities selling similar chemical classes should consider this a signal that digital presence and specific chemical offerings are under agency scrutiny.
Companies operating online chemical or pharmaceutical storefronts must audit all product listings and website claims to ensure they do not meet the definition of an unapproved new drug. Marketing substances for therapeutic or mind-altering effects without appropriate FDA authorization represents a high-risk area for CDER enforcement action.
FDA Warning Letter issued to: Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-arylcyclohexylamine-store-wwwarylcyclohexylaminecom-725151-06232026
Open in openFDA / FDA.gov